Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B

In the phase-III GLOBE/015 studies, telbivudine demonstrated superior efficacy vs lamivudine during 2-year treatment in HBeAg-positive and HBeAg-negative chronic hepatitis B (CHB). After completion, 847 patients had an option to continue telbivudine treatment for further 2 years. A total of 596 (70%...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Y, Thongsawat, S, Gane, E J, Liaw, Y-F, Jia, J, Hou, J, Chan, H L Y, Papatheodoridis, G, Wan, M, Niu, J, Bao, W, Trylesinski, A, Naoumov, N V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2013
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3618368/
https://www.ncbi.nlm.nih.gov/pubmed/23490388
http://dx.doi.org/10.1111/jvh.12025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3618368/
https://www.ncbi.nlm.nih.gov/pubmed/23490388
http://dx.doi.org/10.1111/jvh.12025

Ejemplares similares